# Etanercept in Rheumatoid Arthritis and Vascular Inflammation

> **NCT02109289** · PHASE4 · TERMINATED · sponsor: **Innovaderm Research Inc.** · enrollment: 5 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Vascular Inflammation

## Interventions

- **DRUG:** etanercept

## Key facts

- **NCT ID:** NCT02109289
- **Lead sponsor:** Innovaderm Research Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Recruitment difficulties
- **Last updated:** 2017-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02109289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02109289, "Etanercept in Rheumatoid Arthritis and Vascular Inflammation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02109289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*